Rituximab

The FDA approved ibrutinib in combination with rituximab for treatment of newly diagnosed patients chronic lymphocytic leukemia or small lymphocytic lymphoma.

Initial score on the Pemphigus Disease Area Index and evolution of anti-desmoglein antibody values 3 months after an initial cycle of rituximab are associated with short-term pemphigus relapse, according to a post hoc analysis of a randomized clinical trial published in JAMA Dermatology.

In 2016, the FDA approved the first immunotherapy for lymphoma. Since then, the field has exploded and now, just 4 years later, there are nine FDA-approved immunotherapy options for lymphoma, according to the Cancer Research Institute.

Rituximab may be a promising option for treatment-refractory childhood-onset lupus erythematosus panniculitis, according to a retrospective, observational case series published in JAMA Dermatology.

ORLANDO – Combining all novel drugs – rituximab, lenalidomide and ibrutinib – to treat diffuse large B-cell lymphoma proved more effective than standard chemotherapy and combinations thereof, according to a poster presenter at the ASH Annual Meeting and Exposition.

Polatuzumab combined with bendamustine and rituximab demonstrated encouraging rates of complete response among patients with transplantation-ineligible, relapsed/refractory diffuse large B-cell lymphoma, according to results of a phase 1b/phase 2 trial published in Journal of Clinical Oncology.

Researchers compiled a treatment algorithm for cutaneous manifestations of lupus erythematosus based on data from 104 studies, according to a study presented at the American College of Rheumatology/Association of Rheumatology Professionals annual meeting.

SAN FRANCISCO — Only adalimumab is FDA-approved for the treatment of noninfectious intermediate and posterior uveitis and panuveitis; however, other biologics hold promise for the treatment of ocular inflammation, according to a presentation at Cornea Subspecialty Day at the American Academy of Ophthalmology annual meeting.

ATLANTA — A panel at ACR/ARP 2019 offered an overview of the new guidelines for giant cell arteritis, Takayasu’s syndrome, and polyarteritis nodosa.

ATLANTA — Treatment with repeat doses of rituximab is superior to daily azathioprine for preventing relapse among patients with ANCA-associated vasculitis with a history of relapse, according to data presented at the 2019 ACR/ARP Annual Meeting.